After taking a $73M hit, J&J partner Genmab loses arbitration over royalties on megablockbuster Darzalex

J&J has won an arbitration against Genmab on two matters related to their licensing pact for daratumumab, the antibody perhaps better …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter tak­ing a $73M hit, J&J part­ner Gen­mab los­es ar­bi­tra­tion over roy­al­ties on megablock­buster Darza­lex